Theravance Biopharma
Theravance Biopharma, Inc. is a biopharmaceutical company focused on transforming the treatment of specialty respiratory diseases.
Last updated September 15, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Theravance Biopharma, Inc. aims to transform the treatment of specialty respiratory diseases through the discovery, development and commercialization of medicines. Its focus is to deliver Medicines that Make a Difference in people's lives, and it has developed the FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The company describes itself as a place for collaborators and creative problem-solvers, and states that it is committed to creating and driving shareholder value.
History
Rick E Winningham has served as Chief Executive Officer of Theravance Biopharma since its spin-off from Innoviva in June 2014. He has served on the board of directors since July 2013, including as Chairman until October 2024. From October 2001 to August 2014, he served as Chief Executive Officer of Innoviva, where he also served as Chairman of the board of directors from April 2010 to October 2014.
Products and positioning
Focused on specialty respiratory diseases and delivering Medicines that Make a Difference.
YUPELRI (revefenacin) Inhalation Solution
FDA-approved inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Recent events
Reported
Theravance Biopharma appoints Deepika R. Pakianathan to its board[4]
Theravance Biopharma announced the appointment of Deepika R. Pakianathan, Ph.D. to its board of directors.
Reported
Theravance Biopharma prices public share offering[5]
Theravance Biopharma announced pricing of an underwritten public offering of 5.5 million ordinary shares at $27 per share; the offering was expected to close on February 14, subject to customary conditions.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/theravance-biopharma-us · Editorial policy · How profiles are compiled